Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback